1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) Signaling Capacity and the Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer (NSCLC): Implications for Use of 1,25(OH)2D3 in NSCLC Treatment

1,25-dihydroxyvitamin D3 (1,25(OH)2D3) exerts anti-proliferative activity by binding to the vitamin D receptor (VDR) and regulating gene expression. We previously reported that non-small cell lung cancer (NSCLC) cells which harbor epidermal growth factor receptor (EGFR) mutations display elevated VD...

Full description

Bibliographic Details
Main Authors: Pamela A. Hershberger, Song Liu, Moray Campbell, Maochun Qin, Suzanne Shoemaker, Alissa Verone, Santosh Kumar Upadhyay
Format: Article
Language:English
Published: MDPI AG 2013-11-01
Series:Cancers
Subjects:
Online Access:http://www.mdpi.com/2072-6694/5/4/1504
_version_ 1797708532036927488
author Pamela A. Hershberger
Song Liu
Moray Campbell
Maochun Qin
Suzanne Shoemaker
Alissa Verone
Santosh Kumar Upadhyay
author_facet Pamela A. Hershberger
Song Liu
Moray Campbell
Maochun Qin
Suzanne Shoemaker
Alissa Verone
Santosh Kumar Upadhyay
author_sort Pamela A. Hershberger
collection DOAJ
description 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) exerts anti-proliferative activity by binding to the vitamin D receptor (VDR) and regulating gene expression. We previously reported that non-small cell lung cancer (NSCLC) cells which harbor epidermal growth factor receptor (EGFR) mutations display elevated VDR expression (VDRhigh) and are vitamin D-sensitive. Conversely, those with K-ras mutations are VDRlow and vitamin D-refractory. Because EGFR mutations are found predominately in NSCLC cells with an epithelial phenotype and K-ras mutations are more common in cells with a mesenchymal phenotype, we investigated the relationship between vitamin D signaling capacity and the epithelial mesenchymal transition (EMT). Using NSCLC cell lines and publically available lung cancer cell line microarray data, we identified a relationship between VDR expression, 1,25(OH)2D3 sensitivity, and EMT phenotype. Further, we discovered that 1,25(OH)2D3 induces E-cadherin and decreases EMT-related molecules SNAIL, ZEB1, and vimentin in NSCLC cells. 1,25(OH)2D3-mediated changes in gene expression are associated with a significant decrease in cell migration and maintenance of epithelial morphology. These data indicate that 1,25(OH)2D3 opposes EMT in NSCLC cells. Because EMT is associated with increased migration, invasion, and chemoresistance, our data imply that 1,25(OH)2D3 may prevent lung cancer progression in a molecularly defined subset of NSCLC patients.
first_indexed 2024-03-12T06:24:01Z
format Article
id doaj.art-7e96aef4c4a44542b61121839738b64e
institution Directory Open Access Journal
issn 2072-6694
language English
last_indexed 2024-03-12T06:24:01Z
publishDate 2013-11-01
publisher MDPI AG
record_format Article
series Cancers
spelling doaj.art-7e96aef4c4a44542b61121839738b64e2023-09-03T02:03:59ZengMDPI AGCancers2072-66942013-11-01541504152110.3390/cancers50415041,25-Dihydroxyvitamin D3 (1,25(OH)2D3) Signaling Capacity and the Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer (NSCLC): Implications for Use of 1,25(OH)2D3 in NSCLC TreatmentPamela A. HershbergerSong LiuMoray CampbellMaochun QinSuzanne ShoemakerAlissa VeroneSantosh Kumar Upadhyay1,25-dihydroxyvitamin D3 (1,25(OH)2D3) exerts anti-proliferative activity by binding to the vitamin D receptor (VDR) and regulating gene expression. We previously reported that non-small cell lung cancer (NSCLC) cells which harbor epidermal growth factor receptor (EGFR) mutations display elevated VDR expression (VDRhigh) and are vitamin D-sensitive. Conversely, those with K-ras mutations are VDRlow and vitamin D-refractory. Because EGFR mutations are found predominately in NSCLC cells with an epithelial phenotype and K-ras mutations are more common in cells with a mesenchymal phenotype, we investigated the relationship between vitamin D signaling capacity and the epithelial mesenchymal transition (EMT). Using NSCLC cell lines and publically available lung cancer cell line microarray data, we identified a relationship between VDR expression, 1,25(OH)2D3 sensitivity, and EMT phenotype. Further, we discovered that 1,25(OH)2D3 induces E-cadherin and decreases EMT-related molecules SNAIL, ZEB1, and vimentin in NSCLC cells. 1,25(OH)2D3-mediated changes in gene expression are associated with a significant decrease in cell migration and maintenance of epithelial morphology. These data indicate that 1,25(OH)2D3 opposes EMT in NSCLC cells. Because EMT is associated with increased migration, invasion, and chemoresistance, our data imply that 1,25(OH)2D3 may prevent lung cancer progression in a molecularly defined subset of NSCLC patients.http://www.mdpi.com/2072-6694/5/4/1504epithelial mesenchymal transitionvitamin D1,25-dihydroxyvitamin D3lung cancer, TGFβ
spellingShingle Pamela A. Hershberger
Song Liu
Moray Campbell
Maochun Qin
Suzanne Shoemaker
Alissa Verone
Santosh Kumar Upadhyay
1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) Signaling Capacity and the Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer (NSCLC): Implications for Use of 1,25(OH)2D3 in NSCLC Treatment
Cancers
epithelial mesenchymal transition
vitamin D
1,25-dihydroxyvitamin D3
lung cancer, TGFβ
title 1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) Signaling Capacity and the Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer (NSCLC): Implications for Use of 1,25(OH)2D3 in NSCLC Treatment
title_full 1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) Signaling Capacity and the Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer (NSCLC): Implications for Use of 1,25(OH)2D3 in NSCLC Treatment
title_fullStr 1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) Signaling Capacity and the Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer (NSCLC): Implications for Use of 1,25(OH)2D3 in NSCLC Treatment
title_full_unstemmed 1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) Signaling Capacity and the Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer (NSCLC): Implications for Use of 1,25(OH)2D3 in NSCLC Treatment
title_short 1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) Signaling Capacity and the Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer (NSCLC): Implications for Use of 1,25(OH)2D3 in NSCLC Treatment
title_sort 1 25 dihydroxyvitamin d3 1 25 oh 2d3 signaling capacity and the epithelial mesenchymal transition in non small cell lung cancer nsclc implications for use of 1 25 oh 2d3 in nsclc treatment
topic epithelial mesenchymal transition
vitamin D
1,25-dihydroxyvitamin D3
lung cancer, TGFβ
url http://www.mdpi.com/2072-6694/5/4/1504
work_keys_str_mv AT pamelaahershberger 125dihydroxyvitamind3125oh2d3signalingcapacityandtheepithelialmesenchymaltransitioninnonsmallcelllungcancernsclcimplicationsforuseof125oh2d3innsclctreatment
AT songliu 125dihydroxyvitamind3125oh2d3signalingcapacityandtheepithelialmesenchymaltransitioninnonsmallcelllungcancernsclcimplicationsforuseof125oh2d3innsclctreatment
AT moraycampbell 125dihydroxyvitamind3125oh2d3signalingcapacityandtheepithelialmesenchymaltransitioninnonsmallcelllungcancernsclcimplicationsforuseof125oh2d3innsclctreatment
AT maochunqin 125dihydroxyvitamind3125oh2d3signalingcapacityandtheepithelialmesenchymaltransitioninnonsmallcelllungcancernsclcimplicationsforuseof125oh2d3innsclctreatment
AT suzanneshoemaker 125dihydroxyvitamind3125oh2d3signalingcapacityandtheepithelialmesenchymaltransitioninnonsmallcelllungcancernsclcimplicationsforuseof125oh2d3innsclctreatment
AT alissaverone 125dihydroxyvitamind3125oh2d3signalingcapacityandtheepithelialmesenchymaltransitioninnonsmallcelllungcancernsclcimplicationsforuseof125oh2d3innsclctreatment
AT santoshkumarupadhyay 125dihydroxyvitamind3125oh2d3signalingcapacityandtheepithelialmesenchymaltransitioninnonsmallcelllungcancernsclcimplicationsforuseof125oh2d3innsclctreatment